Holen Sie sich die Stockscreener-App
74.08
2.04%
1.48
Handel nachbörslich:
74.08
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$72.60
Offen:
$72.72
24-Stunden-Volumen:
3.17M
Relative Volume:
1.55
Marktkapitalisierung:
$35.89B
Einnahmen:
$10.03B
Nettoeinkommen (Verlust:
$1.07B
KGV:
34.38
EPS:
2.1549
Netto-Cashflow:
$1.39B
1W Leistung:
-1.71%
1M Leistung:
-5.37%
6M Leistung:
-18.21%
1J Leistung:
-23.78%
1-Tages-Spanne:
$72.65
$74.24
1-Wochen-Bereich:
$71.55
$77.00
52-Wochen-Spanne:
$71.55
$99.20
Alcon Inc Stock (ALC) Company Profile
Vergleichen Sie ALC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
74.08 | 35.89B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
ISRG
Intuitive Surgical Inc
|
436.39 | 156.20B | 9.15B | 2.63B | 1.99B | 7.1661 |
|
BDX
Becton Dickinson Co
|
188.35 | 53.50B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
RMD
Resmed Inc
|
270.15 | 39.84B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
WST
West Pharmaceutical Services Inc
|
261.26 | 18.87B | 2.96B | 487.70M | 344.00M | 6.6758 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-05-14 | Bestätigt | BTIG Research | Buy |
| 2025-03-28 | Bestätigt | Needham | Buy |
| 2025-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-24 | Bestätigt | Needham | Buy |
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
Stifel reiterates Buy rating on Alcon stock, maintains $85 price target - Investing.com
STAAR Surgical Announces Merger with Alcon Amid Legal Challenges - TradingView
How Alcon Inc. stock performs in stagflationQuarterly Trade Review & Free Accurate Trade Setup Notifications - newser.com
Why Alcon Inc. stock is favored by pension fundsPortfolio Update Summary & Risk Managed Trade Strategies - newser.com
BTIG Maintains Alcon (ALC) Buy Recommendation - Nasdaq
Vision Care: Global Market Report 2025 | Leading Vision - GlobeNewswire
Barclays Initiates Coverage on Alcon (ALC) with Equal-Weight Rat - GuruFocus
Alcon Inc. stock trend outlook and recovery pathTrade Volume Summary & Safe Entry Zone Tips - newser.com
Barclays reiterates Equalweight rating on Alcon stock, maintains $86 price target - Investing.com Australia
Alcon Inc. (ALC) Investor Outlook: Eyeing A 35% Upside With Strong Buy Ratings - DirectorsTalk Interviews
Is Alcon Inc. (2U3) stock inflation resilientWeekly Trade Review & Real-Time Stock Movement Alerts - newser.com
Broadwood slams STAAR board over “carelessness” in Alcon sale defense - Investing.com
Is Alcon Now an Opportunity After 29.6% Share Price Slide in 2024? - Yahoo Finance
Alcon stock hits 52-week low at 73.17 USD By Investing.com - Investing.com Canada
Broadwood urges STAAR shareholders to reject Alcon acquisition By Investing.com - Investing.com Canada
Broadwood urges STAAR shareholders to reject Alcon acquisition - Investing.com
Alcon stock hits 52-week low at 73.17 USD - Investing.com
Investor Group Opposes Alcon's Acquisition of STAAR Surgical (AL - GuruFocus
Broadwood issues letter to Staar Surgical board questioning ‘rush’ in Alcon sale - TipRanks
Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale - MarketScreener
How to integrate Alcon Inc. into portfolio analysis toolsStop Loss & Accurate Trade Setup Notifications - newser.com
Short interest data insights for Alcon Inc.Day Trade & Precise Buy Zone Tips - newser.com
Can trapped investors hope for a rebound in Alcon Inc.Bond Market & Community Verified Watchlist Alerts - newser.com
Alcon Stock Rated Buy by BTIG Following TRYPTYR Approval - MSN
What hedge fund moves indicate for Alcon Inc. Ordinary Shares stockNew Guidance & Intraday High Probability Alerts - newser.com
How to forecast Alcon Inc. trends using time seriesTrade Ideas & Daily Price Action Insights - newser.com
What to do if you’re stuck in Alcon Inc.2025 Sector Review & Daily Oversold Bounce Ideas - newser.com
STAAR Surgical Board Defends $1.5 Billion Alcon Acquisition Plan - Finimize
Glass Lewis recommends shareholders vote against STAAR-Alcon deal By Investing.com - Investing.com Nigeria
STAAR urges shareholders to approve Alcon merger despite Glass Lewis report - Investing.com Nigeria
STAAR Surgical’s Long-Term Shareholder Says Proposed Deal With Alcon Undervalues The Company - MSN
Alcon (ALC) Faces Opposition in Staar Surgical Merger Deal - GuruFocus
STAAR Surgical (STAA): Proxy Adviser Urges Rejection of Alcon De - GuruFocus
STAAR urges shareholders to approve Alcon merger despite Glass Lewis report By Investing.com - Investing.com South Africa
Glass Lewis Advises Against Alcon (ALC) Acquisition of STAAR - GuruFocus
STAAR Surgical holders should vote against sale to Alcon, Glass Lewis says - Seeking Alpha
Broadwood and Glass Lewis urge Staar shareholders to vote "against" sale to Alcon - MarketScreener
Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon - The Globe and Mail
Broadwood urges STAAR shareholders to reject Alcon takeover bid - Investing.com
Broadwood Partners Questions Integrity of STAAR Surgical’s Last-Minute Forecast Change and Fairness Opinion in Sale to Alcon | FinancialContent - FinancialContent
Defender Capital Opposes STAAR Surgical's Proposed Acquisition By Alcon - Nasdaq
Defender Capital Opposes STAAR Surgical?s Sale to Alcon - MarketScreener
Alcon's Proposed Acquisition of STAAR Faces Shareholder Oppositi - GuruFocus
Warner Bros. Challenges Alcon Bid for ‘Matrix’ Studio Rights - Bloomberg Law News
Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon - Stock Titan
Yunqi Capital, One Of Staar Surgical Company’S Largest Shareholders, Reiterates Its Opposition To The Proposed Merger With Alcon - TradingView
Yunqi Capital opposes sale of STAAR Surgical to Alcon - Investing.com
Yunqi Capital opposes sale of STAAR Surgical to Alcon By Investing.com - Investing.com Nigeria
Yunqi Capital Challenges Proposed Sale of STAAR to Alcon (ALC) - GuruFocus
Yunqi Capital urges STAAR shareholders to oppose Alcon merger - TipRanks
$62/Share Offer Challenged: STAAR Shareholder Yunqi (5.1%) Reiterates Opposition Ahead of Vote - Stock Titan
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):